Aetna Throws Support Behind Non-invasive Prenatal Tests for Down Syndrome | GenomeWeb

NEW YORK (GenomeWeb News) – Aetna this week issued a clinical policy bulletin suggesting that it may soon begin covering non-invasive prenatal DNA tests for Down syndrome.

In its bulletin, the health insurer said that it "considers measurement of cell-free nucleic acids in maternal blood … medically necessary for testing for fetal aneuploidy (trisomy 13, 18, 21) in pregnant women with single gestations," who meet any one of a set of criteria.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: role for epigenetic in neuronal excitability, and more.

The new Office of Research Integrity director is grappling with complaints from her staff, according to ScienceInsider.

Italian researchers link SNPs in the PDSS2 gene to coffee consumption in a new paper.

A gene-editing ban has been interpreted to include mitochondrial transfer, Technology Review reports.